Abstract:Despite the superior patient and allograft survival rates of HLA‐identical sibling renal transplantation, a substantial incidence of acute rejection still occurs with the conventional azathioprine‐prednisone (AZA‐P) or AZA‐P‐antilymphocyte globulin (ALG) immunosuppressive regimens. In an attempt to further improve these results, we compared a cyclosporine (CSA)‐AZA‐P combination with AZA‐P‐ALG in 60 consecutive HLA‐identical sibling renal allograft recipients. The distribution of gender, age and proportion of diabetics was almost identical between the two groups. There was no significant difference (p = 0.51) between the CSA‐AZA‐P versus AZA‐P‐ALG groups in patient or graft survival at 1 year (100% versus 93%). Renal function was also similar when comparing the best (1.0 ± 0.7 vs 1.0 ± 0.3 mg/dl, p = 0.46) and current serum creatinine concentrations (1.4 ± 0.7 vs 1.4 ± 0.3 mg/dl, p = 0.45). The AZA‐P‐ALG treated group had a 40% incidence of rejections at 6 months, while rejections were totally eliminated in the CSA‐AZA‐P group (p < 0.001). Patients who received CSA‐AZA‐P also had a lower incidence of infections at 6 months posttransplant (3% vs 27%, p = 0.05), and shorter mean hospitalization time posttransplant (7.4 ± 4.3 days vs 12.4 ± 7.7 d, p < 0.001). Our results suggest that the CSA‐AZA‐P combination is safe and extremely effective for immunosuppression in HLA‐identical sibling renal transplantation.

HLA‐identical sibling renal transplants: No rejections with a cyclosporine‐azathioprine‐prednisone protocol